Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2008-9-15
pubmed:abstractText
The aim of this study was to evaluate the effects of a combination of folinic acid, 5-fluorouracil (5FU) and irinotecan (FOLFIRI 1) administered every 2 weeks in a population of elderly subjects with advanced colorectal cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1432-0843
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
62
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
931-6
pubmed:meshHeading
pubmed-meshheading:18273618-Adenocarcinoma, pubmed-meshheading:18273618-Aged, pubmed-meshheading:18273618-Aged, 80 and over, pubmed-meshheading:18273618-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:18273618-Camptothecin, pubmed-meshheading:18273618-Colorectal Neoplasms, pubmed-meshheading:18273618-Combined Modality Therapy, pubmed-meshheading:18273618-Diarrhea, pubmed-meshheading:18273618-Disease-Free Survival, pubmed-meshheading:18273618-Fluorouracil, pubmed-meshheading:18273618-Hematologic Diseases, pubmed-meshheading:18273618-Humans, pubmed-meshheading:18273618-Leucovorin, pubmed-meshheading:18273618-Myocardial Ischemia, pubmed-meshheading:18273618-Organoplatinum Compounds, pubmed-meshheading:18273618-Palliative Care, pubmed-meshheading:18273618-Patient Compliance, pubmed-meshheading:18273618-Prospective Studies, pubmed-meshheading:18273618-Quality of Life, pubmed-meshheading:18273618-Radiotherapy, Adjuvant, pubmed-meshheading:18273618-Survival Analysis
pubmed:year
2008
pubmed:articleTitle
Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
pubmed:affiliation
Centre Antoine-Lacassagne, 33 Ave de Valombrose, 06189, Nice Cedex 2, France. eric.francois@cal.nice.fnclcc.fr
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II